GRIN Therapeutics, Inc.

GRIN-related neurodevelopmental disorder (NDD) is caused by variants in the GRIN gene, which encodes a subunit of the NMDA receptor. These can result in loss-of-function or gain-of-function variants, disrupting normal brain signaling and contributing to symptoms like seizures, intellectual disabilities, and neurobehavioral challenges. The ability to modulate the activity of NMDA receptors holds significant potential for treating this condition, as well as other neurodevelopmental disorders like tuberous sclerosis complex (#TSC) and focal cortical dysplasia (#FCD). Learn more: https://lnkd.in/ePuxaVkx

Early research in our investigational drug radiprodil shows the potential for both anticonvulsant effects and impact on non-seizure outcomes in children with GRIN-related neurodevelopmental disorder (NDD). While current treatment options for GRIN-related NDD focus on symptom management rather than the root cause, our investigational drug radiprodil is intended to target overactive NMDA receptors–a key factor in many patients with this neurodevelopmental disorder. This molecule represents a promising step in precision #neuroscience with the potential to offer a new standard of care for patients. Learn more about how we are translating this science into real-world treatments that have the potential to improve functional outcomes, making a meaningful impact for patients and families: https://lnkd.in/ePuxaVkx

As #AANAM brings together leading experts and pioneers in neurology, we’re thrilled that our CMO Michael Panzara will attend American Academy of Neurology’s Annual Meeting and participate in the panel celebrating the National Institute of Neurological Disorders and Stroke (NINDS) 75th Anniversary.    This milestone event is an opportunity to discuss the latest scientific breakthroughs and advancements in research and treatments, deepening our understanding of neurological disorders. We look forward to the discussions, discoveries, and collaborations that will drive innovation and shape the future of #neurology. 

We’re pleased to share that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to our investigational drug, radiprodil, in the treatment of GRIN-related neurodevelopmental disorder (NDD). This milestone follows our recent Breakthrough Therapy and Orphan Drug designations from the FDA, reflecting the growing recognition of the urgent need for potential treatment options in this rare pediatric condition. See our press release: https://lnkd.in/eYUsQEMR

Today on #PurpleDay, we recognize and support the millions of people living with #epilepsy. Earlier this month, our Director of Community Engagement and Communication, Hillary Savoie, represented our team at the National Epilepsy Walk in Washington, DC, led by the Epilepsy Foundation. Additionally, GRIN Therapeutics was honored as a Neurvati Neurosciences Company to sponsor the Epilepsy Foundation Epilepsy Research Ambassador Program Bootcamp, an initiative focused on educating advocates about research and clinical trials to support their active participation in epilepsy research. As we continue advancing targeted therapies for developmental and epileptic encephalopathies (DEEs), including GRIN-related neurodevelopmental disorder (NDD), tuberous sclerosis complex (#TSC), and focal cortical dysplasia Type II (#FCD), we remain committed to driving innovation and progress in epilepsy research with patients, families, and advocates impacted by this neurological disorder as our driving force. #EpilepsyAwareness #ClinicalResearch #NationalEpilepsyWalk2025 

#DYK that individuals affected by GRIN2D-related neurodevelopmental disorder (NDD) experience moderate-to-severe developmental delays and intellectual disabilities? Common additional challenges include epilepsy, muscular hypotonia, movement disorders, spasticity, feeding difficulties, and behavioral issues. As we observe #GRIN2DAwarenessDay, let's unite to raise awareness, foster understanding, and continue to advocate for increased research to improve the lives of individuals impacted by GRIN2D-related NDD.

Today during the Stifel Virtual CNS Forum our CEO Bruce Leuchter, M.D., will deliver a presentation at 5pm ET to discuss our clinical development programs for GRIN-related neurodevelopmental disorder (NDD) and tuberous sclerosis complex (#TSC) and focal cortical dysplasia Type II (#FCD). We look forward to engaging with investors and #biotech leaders to share insights into our pipeline and the progress we're making in advancing innovative treatments within the #CNS space.

Today, we are excited to announce that the U.S. FDA granted Orphan Drug designation to our investigational drug, radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD). This achievement underscores the rapid progress we are making in our efforts to bring a first-ever treatment for GRIN-related neurodevelopmental disorder to patients, and we look forward to launching our Phase 3 pivotal trial mid-year. See our press release: https://prn.to/4iuxDpG

Today is #GRIN2AAwarenessDay, a day to highlight GRIN2A-related neurodevelopmental disorder (NDD), a condition that can cause developmental delays or intellectual disabilities. Individuals with this disorder may also experience speech difficulties, epilepsy, muscular hypotonia, movement disorders, spasticity, feeding problems, and behavioral issues. GRIN2A-related NDD is caused by variants in the GRIN2A gene, which plays a crucial role in brain function and development. As we advance development of precision therapeutics for the potential treatment of GRIN-related NDD, including GRIN2A-related neurodevelopmental disorder, we are proud to collaborate with advocacy communities to bring attention to this rare condition.

Today, on #GRIN2BAwarenessDay, we proudly stand with the GRIN2B community in raising awareness and supporting patients and families affected by this neurodevelopmental disorder (NDD). Last week, we were honored to join the CureGRIN Foundation and the GRIN2B Foundation for the second webinar in their Clinical Trials Series. During the session, we shared valuable insights into the clinical trial process, study design, and how to get involved as we prepare to launch our Phase 3 pivotal trial for GRIN-related NDD. Watch the full recording to learn more: https://lnkd.in/e6VkM-sZ We are grateful for the opportunity to work alongside the GRIN community and remain committed to advancing research and bringing hope to those affected by GRIN-related NDD.